VANCOMYCIN + CEFTRIAXONE + CLINDAMYCIN + SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE) + FLUOROQUINOLONE + LINEZOLID + RIFAMPIN
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hip Prosthetic Joint Infection
Conditions
Hip Prosthetic Joint Infection
Trial Timeline
Oct 1, 2012 → Apr 1, 2016
NCT ID
NCT01757236About VANCOMYCIN + CEFTRIAXONE + CLINDAMYCIN + SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE) + FLUOROQUINOLONE + LINEZOLID + RIFAMPIN
VANCOMYCIN + CEFTRIAXONE + CLINDAMYCIN + SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE) + FLUOROQUINOLONE + LINEZOLID + RIFAMPIN is a phase 2 stage product being developed by Pfizer for Hip Prosthetic Joint Infection. The current trial status is unknown. This product is registered under clinical trial identifier NCT01757236. Target conditions include Hip Prosthetic Joint Infection.
What happened to similar drugs?
1 of 1 similar drugs in Hip Prosthetic Joint Infection were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01757236 | Phase 2 | UNKNOWN |
Competing Products
1 competing product in Hip Prosthetic Joint Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zoledronic acid 5mg | Novartis | Approved | 35 |